| Literature DB >> 12126906 |
Yu-Lung Lau1, S J Rupert Vessey, Ivan S F Chan, Tsz-Leung Lee, Li-Min Huang, Chin-Yun Lee, Tzou-Yien Lin, Bee Wah Lee, Kow Kwan, Siti M Kasim, Christina Y Chan, Karen M Kaplan, Daniel J Distefano, Anna L Harmon, Amy Golie, Jonathan Hartzel, Jin Xu, Shu Li, Holly Matthews, Jerald C Sadoff, Alan Shaw.
Abstract
This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (approximately 50,000 plaque forming units (PFU), Group A or approximately 16,000 PFU, Group B) or 1 dose of VARILRIX, (approximately 40,000 PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer> or = 5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12126906 DOI： 10.1016/s0264-410x(02)00245-1
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641